MeiraGTx is a pioneering clinical-stage genetic medicine company dedicated to developing potentially curative treatments for patients suffering from serious diseases, both rare and prevalent. With a global presence, MeiraGTx leverages cutting-edge science and innovative technologies, including its advanced riboswitch gene regulation platform, to achieve unprecedented control over gene expression. This enables the customization of genetic therapies, making them applicable to a wide array of disorders beyond inherited diseases.

The company is actively advancing a diverse pipeline of clinical-stage programs targeting conditions such as Parkinson’s disease, xerostomia, and inherited retinal dystrophies. MeiraGTx's commitment to patient welfare is evident in its mission to ensure that every individual receives the best possible treatment. Complemented by a robust end-to-end manufacturing ecosystem and next-generation vector optimization techniques, MeiraGTx is at the forefront of transforming genetic medicine. As they continue to innovate, MeiraGTx aims to improve lives and redefine the future of treatment options in healthcare.